342 related articles for article (PubMed ID: 12579292)
61. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
62. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
Chantapet P; Riantawan P; Lebnak P; Getngern P
J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
[TBL] [Abstract][Full Text] [Related]
63. Skip metastasis in nonsmall cell lung carcinoma: predictive markers and isolated tumor cells in N1 lymph nodes.
Prenzel KL; Baldus SE; Mönig SP; Tack D; Sinning JM; Gutschow CA; Grass G; Schneider PM; Dienes HP; Hölscher AH
Cancer; 2004 May; 100(9):1909-17. PubMed ID: 15112272
[TBL] [Abstract][Full Text] [Related]
64. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
65. Characteristics and prognosis of patients after resection of nonsmall cell lung carcinoma measuring 2 cm or less in greatest dimension.
Okada M; Sakamoto T; Nishio W; Uchino K; Tsubota N
Cancer; 2003 Aug; 98(3):535-41. PubMed ID: 12879471
[TBL] [Abstract][Full Text] [Related]
66. Analysis of risk factors for skip lymphatic metastasis and their prognostic value in operated N2 non-small-cell lung carcinoma.
Benoit L; Anusca A; Ortega-Deballon P; Cheynel N; Bernard A; Favre JP
Eur J Surg Oncol; 2006 Jun; 32(5):583-7. PubMed ID: 16621424
[TBL] [Abstract][Full Text] [Related]
67. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer.
Tomita M; Shimizu T; Ayabe T; Yonei A; Onitsuka T
Anticancer Res; 2010 Jul; 30(7):3099-102. PubMed ID: 20683062
[TBL] [Abstract][Full Text] [Related]
68. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
[TBL] [Abstract][Full Text] [Related]
69. Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation.
Giovanella L; Ceriani L; Bandera M; Rimoldi R; Beghé B; Roncari G
Q J Nucl Med; 1995 Dec; 39(4):285-9. PubMed ID: 8624791
[TBL] [Abstract][Full Text] [Related]
70. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
71. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
Pfannschmidt J; Bade S; Hoheisel J; Muley T; Dienemann H; Herpel E
Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
[TBL] [Abstract][Full Text] [Related]
72. Centre-independent detection of non-small cell lung cancer (NSCLC) by means of classification with receiver operating characteristic (ROC)-based data transformation.
Bitterlich N; Muley T; Schneider J
Anticancer Res; 2010 May; 30(5):1661-5. PubMed ID: 20592358
[TBL] [Abstract][Full Text] [Related]
73. The impact of immunohistochemical detection of positive lymph nodes in early stage lung cancer.
Tezel C; Ersev AA; Kiral H; Urek S; Kosar A; Keles M; Dudu C; Arman B
Thorac Cardiovasc Surg; 2006 Mar; 54(2):124-8. PubMed ID: 16541355
[TBL] [Abstract][Full Text] [Related]
74. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
[TBL] [Abstract][Full Text] [Related]
75. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
[TBL] [Abstract][Full Text] [Related]
76. Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer.
De Petris L; Brandén E; Herrmann R; Sanchez BC; Koyi H; Linderholm B; Lewensohn R; Linder S; Lehtiö J
Eur J Cancer; 2011 Jan; 47(1):131-7. PubMed ID: 20822898
[TBL] [Abstract][Full Text] [Related]
77. Loss of pRb2/p130 expression is associated with unfavorable clinical outcome in lung cancer.
Caputi M; Groeger AM; Esposito V; De Luca A; Masciullo V; Mancini A; Baldi F; Wolner E; Giordano A
Clin Cancer Res; 2002 Dec; 8(12):3850-6. PubMed ID: 12473599
[TBL] [Abstract][Full Text] [Related]
78. Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer.
Pavićević R; Milicić J; Bubanović G; Supe S
Coll Antropol; 1998 Dec; 22(2):629-35. PubMed ID: 9887620
[TBL] [Abstract][Full Text] [Related]
79. Combined detection of CEA, CK-19 and c-met mRNAs in peripheral blood: a highly sensitive panel for potential molecular diagnosis of non-small cell lung cancer.
Sheu CC; Chang MY; Chang HC; Tsai JR; Lin SR; Chang SJ; Hwang JJ; Huang MS; Chong IW
Oncology; 2006; 70(3):203-11. PubMed ID: 16809939
[TBL] [Abstract][Full Text] [Related]
80. Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC.
Ono K; Uramoto H; Hanagiri T
Anticancer Res; 2010 Sep; 30(9):3273-8. PubMed ID: 20944097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
